Abstract
Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic state in heart failure. This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment.
Copyright Thieme Medical Publishers.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Anticoagulants / therapeutic use*
-
Aspirin / therapeutic use
-
Fibrinolytic Agents / therapeutic use
-
Heart Failure, Systolic / complications
-
Heart Failure, Systolic / drug therapy
-
Heart Failure, Systolic / physiopathology*
-
Humans
-
Myocardial Infarction / etiology
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prognosis
-
Pulmonary Embolism / etiology
-
Randomized Controlled Trials as Topic
-
Renin-Angiotensin System / drug effects
-
Thromboembolism / etiology
-
Warfarin / therapeutic use
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Anticoagulants
-
Fibrinolytic Agents
-
Platelet Aggregation Inhibitors
-
Warfarin
-
Aspirin